These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 29719870)
21. Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria. Gauba A; Rahman KM Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998792 [TBL] [Abstract][Full Text] [Related]
22. Identification of a Specific Biomarker of Acinetobacter baumannii Global Clone 1 by Machine Learning and PCR Related to Metabolic Fitness of ESKAPE Pathogens. Álvarez VE; Quiroga MP; Centrón D mSystems; 2023 Jun; 8(3):e0073422. PubMed ID: 37184409 [TBL] [Abstract][Full Text] [Related]
23. ESKAPE in China: epidemiology and characteristics of antibiotic resistance. Luo Q; Lu P; Chen Y; Shen P; Zheng B; Ji J; Ying C; Liu Z; Xiao Y Emerg Microbes Infect; 2024 Dec; 13(1):2317915. PubMed ID: 38356197 [TBL] [Abstract][Full Text] [Related]
24. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens. Saha U; Gondi R; Patil A; Saroj SD Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207 [TBL] [Abstract][Full Text] [Related]
26. Selection of Potential Probiotic Bacteria from Exclusively Breastfed Infant Faeces with Antagonistic Activity Against Multidrug-Resistant ESKAPE Pathogens. Rastogi S; Mittal V; Singh A Probiotics Antimicrob Proteins; 2021 Jun; 13(3):739-750. PubMed ID: 33190215 [TBL] [Abstract][Full Text] [Related]
27. Antibiotic resistance: a global crisis, problems and solutions. Aggarwal R; Mahajan P; Pandiya S; Bajaj A; Verma SK; Yadav P; Kharat AS; Khan AU; Dua M; Johri AK Crit Rev Microbiol; 2024 Sep; 50(5):896-921. PubMed ID: 38381581 [TBL] [Abstract][Full Text] [Related]
28. Fine-Tuning of Alkaline Residues on the Hydrophilic Face Provides a Non-toxic Cationic α-Helical Antimicrobial Peptide Against Antibiotic-Resistant ESKAPE Pathogens. Luo X; Ye X; Ding L; Zhu W; Yi P; Zhao Z; Gao H; Shu Z; Li S; Sang M; Wang J; Zhong W; Chen Z Front Microbiol; 2021; 12():684591. PubMed ID: 34335511 [TBL] [Abstract][Full Text] [Related]
29. Celecoxib Enhances the Efficacy of Low-Dose Antibiotic Treatment against Polymicrobial Sepsis in Mice and Clinical Isolates of ESKAPE Pathogens. Annamanedi M; Varma GYN; Anuradha K; Kalle AM Front Microbiol; 2017; 8():805. PubMed ID: 28533769 [TBL] [Abstract][Full Text] [Related]
30. Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development. Yu H; Xu Y; Imani S; Zhao Z; Ullah S; Wang Q ACS Infect Dis; 2024 Jul; 10(7):2336-2355. PubMed ID: 38866389 [TBL] [Abstract][Full Text] [Related]
31. Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections. Jiang L; Lin J; Taggart CC; Bengoechea JA; Scott CJ J Interdiscip Nanomed; 2018 Sep; 3(3):111-121. PubMed ID: 30443410 [TBL] [Abstract][Full Text] [Related]
32. Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health. Denissen J; Reyneke B; Waso-Reyneke M; Havenga B; Barnard T; Khan S; Khan W Int J Hyg Environ Health; 2022 Jul; 244():114006. PubMed ID: 35841823 [TBL] [Abstract][Full Text] [Related]
33. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens. Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338 [TBL] [Abstract][Full Text] [Related]
34. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections. Ma YX; Wang CY; Li YY; Li J; Wan QQ; Chen JH; Tay FR; Niu LN Adv Sci (Weinh); 2020 Jan; 7(1):1901872. PubMed ID: 31921562 [TBL] [Abstract][Full Text] [Related]
36. Bacteremia due to ESKAPE pathogens: An emerging problem in cancer patients. El-Mahallawy HA; Hassan SS; El-Wakil M; Moneer MM J Egypt Natl Canc Inst; 2016 Sep; 28(3):157-62. PubMed ID: 27268592 [TBL] [Abstract][Full Text] [Related]
37. Quorum Sensing in ESKAPE Bugs: A Target for Combating Antimicrobial Resistance and Bacterial Virulence. Santajit S; Sookrung N; Indrawattana N Biology (Basel); 2022 Oct; 11(10):. PubMed ID: 36290370 [TBL] [Abstract][Full Text] [Related]
38. Antibiotic resistance trends of ESKAPE pathogens in Kwazulu-Natal, South Africa: A five-year retrospective analysis. Ramsamy Y; Essack SY; Sartorius B; Patel M; Mlisana KP Afr J Lab Med; 2018; 7(2):887. PubMed ID: 30568908 [TBL] [Abstract][Full Text] [Related]
39. Antarctic Marine Bacteria as a Source of Anti-Biofilm Molecules to Combat ESKAPE Pathogens. Artini M; Papa R; Vrenna G; Trecca M; Paris I; D'Angelo C; Tutino ML; Parrilli E; Selan L Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887257 [TBL] [Abstract][Full Text] [Related]
40. The therapeutic potential of indole hybrids, dimers, and trimers against drug-resistant ESKAPE pathogens. Qiongxian Y; Jun D; Zhenfeng Z; Tongyou L; Zhicong T; Zhenyou T Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400295. PubMed ID: 38924571 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]